Callisto CEO Dr. Gary S. Jacob Discusses Benefits of Recent $5.14 Million Financing in Online Interview with SmallCapInsights.com; Private Placement Financing to Accelerate Clinical Development of Drug Candidates.LOS ANGELES Los Angeles (lôs ăn`jələs, lŏs, ăn`jəlēz'), city (1990 pop. 3,485,398), seat of Los Angeles co., S Calif.; inc. 1850. -- SmallCapInsights.com, the online source for exclusive commentary, research, interviews and other information about the Smallcap investment marketplace, today announced the availability of the first in a three-part series of exclusive online audio interviews with Dr. Gary S. Jacob, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Chief Scientific Officer of Callisto Pharmaceuticals, Inc. (AMEX AMEX See: American Stock Exchange :KAL) (FWB (Fixed Wireless Broadband) See fixed wireless. :CA4), a developer of new drug treatments in the fight against cancer and other major health threats. In the interview, Dr. Jacob details key benefits of Callisto's recently announced $5.14 million financing. The current interview will focus on the ways in which this financing will reinforce Callisto's clinical development of two lead anti-cancer drugs, L-Annamycin and Atiprimod, both of which have advanced to Phase I/IIa human clinical studies and demonstrated highly encouraging potential for the treatment of acute relapsed and/or refractory forms of blood cancer. "This financing will be extremely advantageous for Callisto's scientific progress," said Dr. Jacob. "The central element of Callisto's strategy and vision is to develop a broad portfolio of new compounds that can give real, viable hope and help to people with acute blood cancers. This multimillion dollar private placement will provide our scientific team with the operating capital Noun 1. operating capital - capital available for the operations of a firm (e.g. manufacturing or transportation) as distinct from financial transactions and long-term improvements capital, working capital - assets available for use in the production of further assets needed to maintain the rapid pace of development that we have been sustaining over the last year." Both L-Annamycin and Atiprimod are now in human clinical studies at prominent institutions including the University of Texas M. D. Anderson Cancer Center. Additional compounds in development by the Company include an exciting new tumor-fighting compound called Degrasyns, recently in-licensed from M. D. Anderson Cancer Center for further development and eventual commercialization, a drug called Guanilib, in development for the treatment of serious inflammatory bowel diseases inflammatory bowel disease n. Abbr. IBD Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. including ulcerative colitis ulcerative colitis Inflammation of the colon, especially of its mucous membranes. The inflamed membranes develop patches of tiny ulcers, and the diarrhea contains blood and mucus. , and a novel bio-defense vaccine for homeland security Noun 1. Homeland Security - the federal department that administers all matters relating to homeland security Department of Homeland Security executive department - a federal department in the executive branch of the government of the United States applications, in a research program funded with U.S. Government support. The interview, the first of three parts to be made available free of charge to all interested investors, can be accessed immediately by visiting http://www.smallcapinsights.com. About Callisto Pharmaceuticals, Inc. Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs for a range of other significant health care market segments, including biodefense. One of the Company's lead drug candidates, L-Annamycin, is being developed as a treatment for forms of relapsed leukemia leukemia (l  kē`mēə), cancerous disorder of the blood-forming tissues (bone marrow, lymphatics, liver, spleen) characterized by excessive production of immature or mature , a currently incurable incurable /in·cur·a·ble/ (in-kur´ah-b'l)1. not susceptible of being cured. 2. a person with a disease which cannot be cured. in·cur·a·ble adj. blood cancer. Callisto initiated a clinical trial of L-Annamycin in adult relapsed acute lymphocytic leukemia acute lymphocytic leukemia n. See acute lymphoblastic leukemia. acute lymphocytic leukemia Acute lymphoblastic leukemia, ALL A malignant lymphoproliferative process that commonly affects children and young adults patients in 4Q 2005. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Another anti-cancer drug, Atiprimod, is in development to treat relapsed multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility , a blood cancer. Atiprimod has entered Phase I/IIa human clinical trials in relapsed multiple myeloma patients. Callisto also has drugs in preclinical development for gastro-intestinal inflammation, and a program focused on the development of a drug to protect against Staphylococcus staphylococcus (stăf'ələkŏk`əs), any of the pathogenic bacteria, parasitic to humans, that belong to the genus Staphylococcus. The spherical bacterial cells (cocci) typically occur in irregular clusters [Gr. and Streptococcus streptococcus (strĕp'təkŏk`əs), any of a group of gram-positive bacteria, genus Streptococcus, some of which cause disease. biowarfare agents. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. For investor-specific information about Callisto, including recent news and stock price data, please visit http://www.trilogy-capital.com/tcp/callisto/. For an Investor Fact Sheet about Callisto, please visit http://www.trilogy-capital.com/tcp/callisto/factsheet.html. To view an informational presentation of the Company's development pipeline of drug candidates, visit http://www.trilogy-capital.com/tcp/callisto/powerpoint.html. Callisto is also listed on the Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors CA4. For additional information, visit www.callistopharma.com. About SmallCapInsights.com SmallCapInsights.com is the online source for exclusive commentary, research, interviews and other information about the Smallcap investment marketplace. We strive to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on SmallCapInsights.com will include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. The Smallcap world is unique: it's filled with development-stage companies that are commercializing cutting-edge technology and executing bold business plans. There are high-growth opportunities available. To make the best decisions, investors need two things: information and insight. That's what SmallCapInsights.com is all about. Compensation and Other Disclosures SmallCapInsights.com is a wholly-owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations Investor relations The process by which the corporation communicates with its investors. services to public companies. The companies presented by SmallCapInsights.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. KAL is contracted to pay Trilogy $12,500 per month through July 2006 and thereafter for so long as Trilogy is retained to provide investor relations services. In connection with its engagement, Trilogy received non-transferable warrants from KAL to purchase 1,793,322 shares of common stock for $1.03 per share expiring in July 2008, provided that the warrants are not exercisable to the extent that following exercise Trilogy would beneficially own 5% or more of the outstanding common stock of the company. Forward-Looking Statements Statements made in this press release or on SmallcapInsights.com may contain forward-looking statements made by senior management of the companies presented here that involve risks and uncertainties, such as statements about plans, objectives, expectations, assumptions or future events. These statements involve estimates, assumptions, known and unknown risks, uncertainties and performances, or achievements expressed or implied by the forward-looking statements. Actual future results and trends may differ materially from those made in -- or suggested by -- statements presented here due to a variety of factors. Consequently, you should not place undue reliance on any forward-looking statements made here. Many of these and other risks and uncertainties are discussed in greater detail in recent filings with the Securities Exchange Commission for the companies that are present by SmallCapInsights.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion